The author discusses Aliskiren's effectiveness as an antihypertensive agent. Aliskiren is the first available rennin inhibitor that acts by selectively binding rennin, blocking its catalytic activity and interfering with its ability to cleave angiotensin I from plasma angiotensinogen. He claims Aliskiren is an effective antihypertensive agent with blood pressure reducing capabilities comparable with that of ACE inhibitors and ARBs. Aliskiren may also be effective in heart failure and diabetes.

Aliskiren:will a novel mechanism improve clinical outcomes? / DE ROSA, MARIA LEONARDA. - In: THE JOURNAL OF CLINICAL HYPERTENSION. - ISSN 1524-6175. - STAMPA. - 12:Suppl 1(2010), pp. A107-A107.

Aliskiren:will a novel mechanism improve clinical outcomes?

DE ROSA, MARIA LEONARDA
2010

Abstract

The author discusses Aliskiren's effectiveness as an antihypertensive agent. Aliskiren is the first available rennin inhibitor that acts by selectively binding rennin, blocking its catalytic activity and interfering with its ability to cleave angiotensin I from plasma angiotensinogen. He claims Aliskiren is an effective antihypertensive agent with blood pressure reducing capabilities comparable with that of ACE inhibitors and ARBs. Aliskiren may also be effective in heart failure and diabetes.
2010
Aliskiren:will a novel mechanism improve clinical outcomes? / DE ROSA, MARIA LEONARDA. - In: THE JOURNAL OF CLINICAL HYPERTENSION. - ISSN 1524-6175. - STAMPA. - 12:Suppl 1(2010), pp. A107-A107.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/376572
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact